SFDMF
Shanghai Fudan Microelectronics Co Limited$3.88 +0.00 (+0.00%)
Oct 26 4:00 PM ET · prev $3.88
Since first trade
−28.8%
from $5.45 · May 6
30 days
0.0%
from $3.88
Range since listing
$3.88–5.45
−29% from high · low Jun 16
Avg volume 20D
0
Sep 29 spike 0
Short interest
🔒 Subscribers only
Price
Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.
No data for this timeframe.
- E May 20 Trial readout: T-90d Trial Readout: FDA018-ADC (Phase 3)
- E May 25 Trial readout: T-90d Trial Readout: FDA018-ADC (Phase 3)
- X Jul 31 Short interest jumps 25.0% to 5.0K
- X Aug 14 Short interest jumps 3340.0% to 172.0K
- X Sep 30 Short interest falls 43.0% to 98.0K
Signal stack
Where each data set points today.
- TrendRANGE
0% above its 50-day average. New closing low $3.88 on Oct 26.
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
May 24, 2026 Clinical trial readout
T-90d Trial Readout: FDA018-ADC (Phase 3)
Trial: FDA018-ADC vs Investigator's Choice Chemotherapy to Treat Locally Advanced, Recurrent or Meta
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
May 24, 2026
Trial readout
T-90d Trial Readout: FDA018-ADC (Phase 3)
Trial: FDA018-ADC vs Investigator's Choice Chemotherapy to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer Sponsor…
May 19, 2026
Trial readout
T-90d Trial Readout: FDA018-ADC (Phase 3)
Trial: FDA018-ADC vs Investigator's Choice Chemotherapy to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer Sponsor…
May 20, 2026
Clinical Trial
Investigating the Safety and Efficacy of SHR6508 Injection in the Treatment of Secondary Hyperparathyroidism in Hemodialysis Patients : A Multicenter, Long-term Clinical Trial
Phase 2 · COMPLETED
May 15, 2026
Clinical Trial
A Study of MRG004A in Patients With Tissue Factor Positive Advanced or Metastatic Solid Tumors
Phase 2 · COMPLETED
May 13, 2026
Clinical Trial
Safety and Pharmacodynamics of SHR-1707 in Alzheimer's Disease Patients
Phase 2 · TERMINATED
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | — | — | — | $0.00 |
| Next Q | — | — | — | $0.00 |
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | — | — | — | $6.6B |
Short side
FINRA· Oct 15, 2026🔒 Subscribers only
shares short